2023
Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023
Dalton A, Diallo A, Chard A, Moulia D, Deputy N, Fothergill A, Kracalik I, Wegner C, Markus T, Pathela P, Still W, Hawkins S, Mangla A, Ravi N, Licherdell E, Britton A, Lynfield R, Sutton M, Hansen A, Betancourt G, Rowlands J, Chai S, Fisher R, Danza P, Farley M, Zipprich J, Prahl G, Wendel K, Niccolai L, Castilho J, Payne D, Cohn A, Feldstein L, Group C, Group C, Saadeh K, Snyder R, Anderson M, Anguiano V, Nadle J, Rothrock G, Jones S, Duval L, Herlihy R, Stringer G, Weber R, Phan Q, Sosa L, Meek J, Lee M, Morrow A, Willut C, Carlson J, Kamis K, Nishiyama M, Simien G, Colasanti J, van der Woude T, Archer R, Finn L, Lam J, Moulton B, Peterson E, Bolan R, Garcia-Lopez G, Como-Sabetti K, Ruff A, Schneider D, Robinson T, Anderson B, Engesser K, McGuire S, Rowe A, Pride C, Mitchell J, Tourkina Y, Cieslak P, Fill M, Wiedeman C, Dumyati G, Felsen C, Lewnard J, Akoko B, Mansilla-Dubon K, Ndi D, Talbot H, Tiwari S, Wyatt D. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 553-558. PMID: 37200229, PMCID: PMC10205167, DOI: 10.15585/mmwr.mm7220a3.Peer-Reviewed Original ResearchMeSH KeywordsAdultCase-Control StudiesHomosexuality, MaleHumansMaleMonkeypoxSexual and Gender MinoritiesSmallpox VaccineUnited StatesConceptsAdjusted vaccine effectivenessVaccine effectivenessCase-control studyFull vaccinationEmerging Infections Program sitesEmergency use authorizationDuration of protectionPrevention of smallpoxImmunocompetent participantsImmunocompromised participantsControl patientsImmunization PracticesPartial vaccinationIntradermal injectionSubcutaneous injectionVaccinationMonkeypox casesAdministration routeDrug AdministrationVaccine accessLaboratory capacityTransgender adultsVaccineTransgender personsAdvisory Committee
2016
Case-Control Study of Vaccine Effectiveness in Preventing Laboratory-Confirmed Influenza Hospitalizations in Older Adults, United States, 2010–2011
Havers F, Sokolow L, Shay D, Farley M, Monroe M, Meek J, Kirley P, Bennett N, Morin C, Aragon D, Thomas A, Schaffner W, Zansky S, Baumbach J, Ferdinands J, Fry A. Case-Control Study of Vaccine Effectiveness in Preventing Laboratory-Confirmed Influenza Hospitalizations in Older Adults, United States, 2010–2011. Clinical Infectious Diseases 2016, 63: 1304-1311. PMID: 27486114, DOI: 10.1093/cid/ciw512.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCase-Control StudiesFemaleHospitalizationHumansImmunizationInfluenza VaccinesInfluenza, HumanMaleMiddle AgedUnited StatesConceptsLaboratory-confirmed influenza hospitalizationsCase-control studyInfluenza hospitalizationsCase patientsAge groupsRecent hospitalizationRespiratory conditionsLower functional status scoresOlder adultsConditional logistic regression modelsAdjusted VE estimatesInfluenza-associated complicationsVaccine effectiveness dataChronic medical conditionsFunctional status scoresMonths of hospitalizationChronic health conditionsLogistic regression modelsPreventing LaboratoryInfluenza vaccinationVaccination statusVaccine effectivenessInfluenza seasonVE estimatesInfluenza infection
2014
Child, Household, and Caregiver Characteristics Associated with Hospitalization for Influenza Among Children 6–59 Months of Age
Dharan N, Sokolow L, Cheng P, Gargiullo P, Gershman K, Lynfield R, Morin C, Thomas A, Meek J, Farley M, Arnold K, Reingold A, Craig A, Schaffner W, Bennett N, Zansky S, Baumbach J, Lathrop S, Kamimoto L, Shay D. Child, Household, and Caregiver Characteristics Associated with Hospitalization for Influenza Among Children 6–59 Months of Age. The Pediatric Infectious Disease Journal 2014, 33: e141-e150. PMID: 24642518, PMCID: PMC4025593, DOI: 10.1097/inf.0000000000000283.Peer-Reviewed Original ResearchConceptsMonths of ageChildren 6Influenza hospitalizationsInfluenza illnessInfluenza vaccinationMaternal ageRisk factorsSevere outcomesChronic illnessEmerging Infections Program sitesLaboratory-confirmed influenza infectionIndependent risk factorInfluenza-associated hospitalizationsYoung maternal ageCase-control studyConditional logistic regressionYoung childrenHematologic/Influenza immunizationHousehold smokingEligible casesInfluenza infectionNeurologic conditionsEligible controlsMedical records
2013
Effectiveness of Nonadjuvanted Monovalent Influenza A(H1N1)pdm09 Vaccines for Preventing Reverse Transcription Polymerase Chain Reaction–Confirmed Pandemic Influenza Hospitalizations: Case-Control Study of Children and Adults at 10 US Influenza Surveillance Network Sites
Thompson M, Sokolow L, Almendares O, Openo K, Farley M, Meek J, Ray J, Kirley P, Reingold A, Aragon D, Hancock E, Baumbach J, Schaffner W, Thomas A, Lynfield R, Ryan P, Monroe M, Cheng P, Fry A, Shay D. Effectiveness of Nonadjuvanted Monovalent Influenza A(H1N1)pdm09 Vaccines for Preventing Reverse Transcription Polymerase Chain Reaction–Confirmed Pandemic Influenza Hospitalizations: Case-Control Study of Children and Adults at 10 US Influenza Surveillance Network Sites. Clinical Infectious Diseases 2013, 57: 1587-1592. PMID: 23956169, PMCID: PMC7314184, DOI: 10.1093/cid/cit551.Peer-Reviewed Original ResearchConceptsLaboratory-confirmed pandemic influenzaCommunity-matched controlsCase-control studyReverse transcription-polymerase chain reactionTranscription-polymerase chain reactionInfluenza hospitalizationsMonovalent influenzaPandemic influenzaSingle dosePolymerase chain reactionVirus infectionInfluenzaChain reactionHospitalizationVaccinePatientsInfectionDoseSelection of Neighborhood Controls for a Population-Based Lyme Disease Case-Control Study by Using a Commercial Marketing Database
Connally NP, Yousey-Hindes K, Meek J. Selection of Neighborhood Controls for a Population-Based Lyme Disease Case-Control Study by Using a Commercial Marketing Database. American Journal Of Epidemiology 2013, 178: 276-279. PMID: 23696105, DOI: 10.1093/aje/kws464.Peer-Reviewed Original Research
2011
Leveraging State Immunization Information Systems to Measure the Effectiveness of Rotavirus Vaccine
Cortese M, LeBlanc J, White K, Jerris R, Stinchfield P, Preston K, Meek J, Odofin L, Khizer S, Miller C, Buttery V, Mijatovic-Rustempasic S, Lewis J, Parashar U, Immergluck L. Leveraging State Immunization Information Systems to Measure the Effectiveness of Rotavirus Vaccine. Pediatrics 2011, 128: e1474-e1481. PMID: 22084328, PMCID: PMC8202521, DOI: 10.1542/peds.2011-1006.Peer-Reviewed Original ResearchConceptsImmunization Information SystemVaccine effectivenessControl groupState Immunization Information SystemRotavirus vaccine effectivenessRotavirus-negative controlsVaccine-eligible childrenEffectiveness of vaccinesVE point estimatesCase-control methodologyYears of lifeRotavirus diseaseRotavirus vaccineNegative childrenEmergency departmentRotavirus seasonRotavirus antigenImmunization recordsEligibility criteriaUS childrenImmunization dataMonthsDosesZip codesChildren
2009
Peridomestic Lyme Disease Prevention Results of a Population-Based Case–Control Study
Connally NP, Durante AJ, Yousey-Hindes KM, Meek JI, Nelson RS, Heimer R. Peridomestic Lyme Disease Prevention Results of a Population-Based Case–Control Study. American Journal Of Preventive Medicine 2009, 37: 201-206. PMID: 19595558, DOI: 10.1016/j.amepre.2009.04.026.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAnimalsCase-Control StudiesChildChild, PreschoolConnecticutEnvironment DesignEnvironmental ExposureFemaleHumansHygieneInfantLogistic ModelsLyme DiseaseMaleMatched-Pair AnalysisMiddle AgedPopulation SurveillanceProspective StudiesResidence CharacteristicsRisk FactorsSurveys and QuestionnairesTicksYoung AdultConceptsCase-control studyLyme diseaseDisease prevention initiativesConditional logistic regressionDisease prevention measuresErythema migransPotential confoundersRecreational exposureLogistic regressionProspective ageDiseaseCase onsetPrevention resultsPrevention measuresPersonal protectionRiskHoursConfoundersMigransTicksInfectionStudyConnecticut communitiesMonths